BETA
Your AI-Trained Oncology Knowledge Connection!
Stay up to date on recent advances in the multidisciplinary approach to cancer.
The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC
AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.
Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Novel Targeted Therapy Shows Promise in PSMA-Positive Prostate Cancer
225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.
PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management
Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.
Zidesamtinib May Yield Meaningful Outcomes in Advanced ROS1+ NSCLC
Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.
Isatuximab Combo Shows Preliminary Activity in Pretreated Multiple Myeloma
More than 70% of patients achieve an objective response with isatuximab plus pomalidomide and dexamethasone in the phase 2 EAE115 trial.
